TSS
SLXN

Two Sigma Securities’s Silexion Therapeutics SLXN Stock Holding History

Two Sigma Securities’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9K Buy
+1,166
New +$20.4K ﹤0.01% 1419
2024
Q4 		– Sell
-11
Closed -$7.94K – 3447
2024
Q3 		$7.94K Buy
+11
New +$17.3K ﹤0.01% 2634

Other funds holding SLXN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Two Sigma Securities's SLXN Position: Q1 2026 in Review

Two Sigma Securities opened a new position in Silexion Therapeutics (SLXN) in Q1 2026: 1,166 shares worth $14.9K. The stake represents ﹤0.01% of the portfolio and ranks #1419 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in SLXN as recently as Q3 2024.

Two Sigma Securities first reported a position in SLXN in Q3 2024 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold SLXN as of Q1 2026.

  • Two Sigma Securities held 1,166 shares of Silexion Therapeutics worth $14.9K as of Q1 2026.
  • Silexion Therapeutics was a new Two Sigma Securities position in Q1 2026.
  • Silexion Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1419 holding.
  • Two Sigma Securities first reported a position in Silexion Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.